High Court Refuses To Hear Authorized Generics Suit

Law360, New York (June 25, 2007, 12:00 AM EDT) -- The U.S. Supreme Court on Monday refused to hear the tamoxifen citrate antitrust lawsuit, meaning it will not weigh in on the legal issues surrounding authorized generics.

The move to deny cert was a victory for Barr Pharmaceuticals Inc., which had argued that a patent litigation settlement agreement it reached with AstraZeneca PLC in 1993 did not violate antitrust or consumer protection statutes.

“We have always believed that our patent challenge settlement related to tamoxifen citrate was pro-consumer and pro-competitive, and this has now been definitively...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.